InvestorsHub Logo
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

Re: modrica post# 3131

Friday, 09/16/2016 11:58:01 AM

Friday, September 16, 2016 11:58:01 AM

Post# of 50154
I found it very interesting due to Delcath receives new FDA approval back in 2015 for "a type of liver cancer that affects bile ducts". it seems they did some major steps forward since then( beside closed $35 Million Funding Round back in June 2016,"One of the targets is in the Phase 2 and Phase 3 study of its Melphalan/HDS").

http://poststar.com/business/local/delcath-receives-new-fda-approval/article_0d206ce0-cfe0-5fa2-97cc-d7c911d1848d.html

DCTH ($6m cap Company, 1.5m O/S) mentioned, just recently, as a major key player for Bile Duct Cancer,among big name companies : http://finance.yahoo.com/news/world-bile-duct-cancer-cholangiocarcinoma-150500717.html

based on last 10Q only,cash burn rate was about 5m(for six month).i would say 40m(cash+restricted) should be sufficient for 3 yrs.imo

Many events (Sept/Oct/Nov) makes it more interesting: http://delcath.com/reuters-events-roll/





My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DCTH News